Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 6/20 | 0.59 |
| ▸ | CTSL | P07711 | 5/20 | 0.59 |
| ▸ | CTSS | P25774 | 3/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13323764 | 0.93 | CTSB (0.58) | CTSBCTSLCTSSCTSKCYP3A4 | |
| SCHEMBL13863704 | 0.91 | CTSB (0.56) | CTSBCTSLCTSSITGB3ITGA2B | |
| SCHEMBL5188996 | 0.91 | CTSB (0.56) | CTSBCTSLCTSSITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL4576415 | 0.90 | CTSB (0.57) | CTSBCTSLCTSSCTSKCYP3A4 | |
| Trifluoroacetic Acid SCHEMBL27715157 | 0.90 | CTSB (0.57) | CTSBCTSLCTSSCTSKCYP3A4 | |
| SCHEMBL5634418 | 0.88 | GPR132 (0.58) | CTSBCTSLCTSSITGB3ITGA2B | |
| SCHEMBL5634425 | 0.88 | GPR132 (0.58) | CTSBCTSLCTSSITGB3ITGA2B | |
| SCHEMBL31084239 | 0.88 | GPR132 (0.58) | CTSBCTSLCTSSITGB3ITGA2B | |
| SCHEMBL3820572 | 0.88 | ACE (0.53) | CTSBCTSLCTSSCTSKCYP3A4 | |
| SCHEMBL13323787 | 0.87 | CTSB (0.55) | CTSBCTSLCTSSCTSKCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AAAS, PGLS, NRDC | CTSB 313/4885CTSL 360/4885CTSS 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.